
Please try another search
Investing.com -- Shares in ImmunoGen (NASDAQ:IMGN) jumped in early trading on Friday after analysts at Barclays raised their price target for the stock to $20 from $9, citing positive commentary around the biotech company's ovarian cancer treatment.
In a note to clients, the Barclays analysts said data presented by the firm for its Elahere ovarian cancer drug at the recent American Society of Clinical Oncology conference were "well received," adding that some observers believe the treatment can be "practice changing."
ImmunoGen previously announced in May that a late-stage trial showed that Elahere helped extend the lives of patients without the cancer worsening, particularly when compared to chemotherapy. Analysts at Truist Securities told Reuters at the time the result was a "home run" for ImmunoGen and all but removes doubt that the drug candidate will eventually receive approval from U.S. drug regulators.
Elsewhere on Friday, ImmunoGen announced updated interim results of a Phase 2 trial of its pivekimab for people with a rare blood cancer. The co-investigator of the study said there was "impressive anti-tumor activity and durable responses" in both frontline and relapsed patients, adding that pivekimab has the potential to be a "promising, novel option for this challenging disease."
When measuring from Thursday's closing price, shares in ImmunoGen have now climbed 217% so far this year.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.